Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Peter O'Donnell
University of Chicago, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
PrescriptIQ
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. O'Donnell is the PI on this project and is therefore responsible for the overall design, conduct and reporting of the research. He recently founded a company, PresciptIQ and is named on the patent application for software titled "Genomic Prescribing System" that has been developed for pharmacogenomic implementation. An early version of this software has been licensed to PrescriptIQ.
The 1200 Patients Project: Studying Clinical Implementation of Pharmacogenomics
Physicians and patients have become increasingly aware that people often react or respond to medications very differently-even when a medication is being used to treat the same condition-and recent research is showing that there may be genetic explanations for this variation between people (pharmacogenomics). Routine consideration of genetic information about drugs could lead to more informed prescribing of medications, allowing treatments to be chosen and/or dosed based upon each individual's personal risk of developing side-effects, balanced against his or her individual chance of receiving benefit. On a population scale, it has the potential to reduce the significant burden of illness caused by drug-induced complications.
Filed on January 17, 2017.
Tell us what you know about Peter O'Donnell's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.